Case Studies

An NIH study of treatments for high blood pressure, called the ALLHAT trial, shows some of the strengths and limitations of comparative effectiveness research to improve patient care. More...

Recent Blog Posts

February 3, 2012 |

On Tuesday night, PIPC Chairman Tony Coelho joined former HHS Secretary Tommy Thompson at the University of Charleston in West Virginia for a speaker series titled "Who Decides Patient Treatments" to discuss the future of health care in the United States.

| Read More
January 30, 2012 |

PCORI released a draft of their National Priorities for Research and Research Agenda for public comment. The PCORI Board, which is responsible for funding research, is asking for a 55 day public comment period to discuss and solicit feedback from patients, caregivers, professionals, and the general public on the research priorities.

In the draft, PCORI prioritized five broad research areas:

| Read More
October 18, 2011 |

When conducting Comparative Effectiveness Research it is crucial to understand the differences between the players involved in the process. In his remarks at the  2nd Annual Forum on Achieving Patient centeredness , Marc Boutin, executive vice president and COO at the National Health Council, discussed the important differences between the three major players in the process: the patient, the consumer, and the patient advocacy organization. He stated that many times when the patient is discussed they are not defined.

| Read More

For Reporters

For journalists and other media professionals

More Information

Stay Connected

PIPC Comments on Federal Coordinating Council and Institute of Medicine CER Recommendations

WASHINGTON, July 8, 2009 – In response to the recent Federal Coordinating Council (FCC) and the Institute of Medicine (IOM) comparative effectiveness recommendations to Congress, Chairman of the Partnership to Improve Patient Care (PIPC), Tony Coelho, issued the following statement:

On behalf of the Partnership to Improve Patient Care (PIPC), I want to thank the Federal Coordinating Council (FCC) and the Institute of Medicine (IOM) for their hard work and thoughtful recommendations to Congress on the issue of comparative effectiveness research (CER).

Their advice to strengthen comparative effectiveness research by focusing on minority and underrepresented populations and ensuring that information is widely disseminated to doctors and patients is especially important to members of underserved communities like African-Americans, Latinos, Asian-Americans, and the disabled. 

We also agree with the FCC that ongoing participation by all stakeholders is critical as CER is developed and that there be transparency in every step of the process, allowing enough time for public consideration and comment, from research design to its implementation and finally its dissemination.

We hope that the FCC and IOM continue to see the importance of CER in providing information to patients and providers, as well as the risks associated with using cost analysis associated with CER for treatment decisions.

Comparative effectiveness research is not about dictating what kind of care should be provided, it's about providing patients and doctors with the information they need to make the best medical decisions.

PIPC is encouraged with the ongoing efforts of Sens. Max Baucus (D-MT) and Kent Conrad (D-ND) and Rep. Kurt Schrader (D-OR) who have authored strong, patient-centered CER bills (S. 1213 and H.R. 2502) and we encourage lawmakers on both sides of the aisle to advance CER within their framework.

We look forward to working with Secretary Sibelius, the Federal Coordinating Council, other members of the Administration, and Members of Congress as they work through the legislative process.


About PIPC
The Partnership to Improve Patient Care was formed in November 2008 to support new comparative effectiveness research proposals that are centered on patient and provider needs; raise awareness about the value of well-designed CER; and promote the important role of continued medical innovation as part of the solution to cost and quality challenges in health care. Partnership members include a wide range of healthcare organizations representing patient, provider and industry advocacy groups.  

AttachmentSize
PIPC_FCC_IOM_Statement_07082009.pdf63.28 KB